Avitide, Inc., the industry leader in the discovery, and manufacture of exclusive biopharmaceutical affinity purification solutions, today announced the closing of a Series E financing. Sands Capital Ventures, LLC led the financing round with participation from Mithril Capital Management, Polaris Partners, NeoMed Management, OrbiMed Advisors, and Borealis Ventures. Ian Ratcliffe (Sands Capital Ventures) joined Avitide’s Board of Directors.
Recent Posts
- FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company
- Vets First Choice Wins Approval to Build New Headquarters in Downtown Portland
- Evox Therapeutics completes £35 million Series B financing
- Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-generation Antibody-based Therapeutics into the Clinic
- Autodesk acquires Assemble Systems to build up its construction tech vertical
Archives
- October 2018 (1)
- September 2018 (2)
- July 2018 (2)
- May 2018 (1)
- April 2018 (1)
- January 2018 (2)
- September 2017 (1)
- August 2017 (1)
- July 2017 (5)
- June 2017 (2)
- April 2017 (1)
- November 2016 (1)
- September 2016 (1)
- April 2016 (2)
- March 2016 (1)
- February 2016 (1)
- January 2016 (2)
- December 2015 (4)
- November 2015 (2)
- September 2015 (1)
- August 2015 (1)
- July 2015 (4)
- June 2015 (5)
- May 2015 (3)
- April 2015 (1)
- March 2015 (1)
- January 2015 (3)
- November 2014 (3)
- October 2014 (4)
- September 2014 (2)
- July 2014 (1)
- June 2014 (1)
- May 2014 (3)
- October 2013 (1)
- August 2013 (1)
- June 2013 (1)
- May 2013 (2)
- March 2013 (2)
- November 2012 (1)
- October 2012 (2)
- April 2012 (1)